(RTTNews) - Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq) for the treatment of ...
Credit: Genentech Ocrevus Zunovo is supplied in a single-dose vial containing 920mg of ocrelizumab and 23,000 units hyaluronidase per 23mL. Ocrevus Zunovo is a combination of ocrelizumab ...
Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics's Enhanze ...
When Roche's Genentech gained approval for Ocrevus in 2017, the first-in-class infused drug quickly became the best-selling treatment in a crowded multiple sclerosis (MS) market. Three years later ...
Roche announced that the United States Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and ...
Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for an injectable version of its blockbuster multiple sclerosis therapy Ocrevus, cutting down the time needed ...
SAN DIEGO - Halozyme (NASDAQ:HALO) Therapeutics, Inc. (NASDAQ: HALO) announced today that the U.S. Food and Drug Administration (FDA) has approved OCREVUS ZUNOVO™, a new formulation for the ...
Roche said regulatory review of this drug is ongoing in additional markets. FDA approval of the MS drug, Ocrevus Zunovo, came the day after the cancer drug approval. Like infused Ocrevus ...
SAN DIEGO - Halozyme (NASDAQ:HALO) Therapeutics, Inc. (NASDAQ: HALO) announced today that the U.S. Food and Drug Administration (FDA) has approved OCREVUS ZUNOVO™, a new formulation for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback